Teduglutide vs Semaglutide
The distinction that mattersGLP-1 and GLP-2 are different hormones from the same precursor gene with opposite therapeutic aims: GLP-1 drugs reduce intake and slow the gut, GLP-2 drugs grow the gut to absorb more.
| Teduglutide FDA Approved | Semaglutide FDA Approved | |
|---|---|---|
| Evidence rating |
5/5 Very strong
Evidence rating 5 out of 5: Very strong
|
5/5 Very strong
Evidence rating 5 out of 5: Very strong
|
| Regulatory status | FDA-approved (2012) for short bowel syndrome in patients dependent on parenteral support. | FDA-approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction in obesity |
| Category | Gut & Gastrointestinal | Metabolic & Weight |
| Drug class | GLP-2 receptor agonist — 33-amino-acid analog resistant to DPP-4 | GLP-1 receptor agonist — 31-amino-acid acylated analog of human GLP-1 |
| Route | Subcutaneous, once daily | Subcutaneous, once weekly (oral tablet daily formulation also marketed) |
| Half-life | ~2 hours | ~7 days (fatty-acid acylation drives albumin binding) |
| Studied in | STEPS phase 3 program and long-term extension studies in short bowel syndrome with intestinal failure. | STEP program (obesity), SUSTAIN program (type 2 diabetes), SELECT (cardiovascular outcomes), STEP-HFpEF (heart failure with preserved ejection fraction), FLOW (diabetic kidney disease). |
| Who should avoid it |
|
|
| Legal status | Prescription drug, typically prescribed through specialist intestinal failure centres. | Prescription drug. Compounded versions are permitted only under specific FDA conditions, which have narrowed as shortages resolved. Peptides sold online as "research semaglutide" are unapproved and unverified. |
Benefits — Teduglutide
- Reduces parenteral nutrition dependence
A substantial proportion of patients achieved clinically meaningful reductions in weekly parenteral support volume, and some achieved complete independence from it.
- Genuine mucosal growth
Biopsy-confirmed increases in villus height and crypt depth — structural change, not just symptom improvement.
- Reduces infusion days per week
Fewer nights tethered to a pump, with direct quality-of-life consequences.
- Durable with continued therapy
Extension studies show benefit maintained over years of treatment.
Benefits — Semaglutide
- Substantial, durable weight loss
In the 68-week STEP 1 trial, adults without diabetes lost roughly 15% of body weight on 2.4 mg weekly versus about 2.4% on placebo — a magnitude previously seen only with bariatric surgery.
- Strong glycemic control
HbA1c reductions on the order of 1.5–1.8 percentage points across the SUSTAIN trials, with low intrinsic hypoglycemia risk because insulin release is glucose-dependent.
- Cardiovascular event reduction
The SELECT trial in patients with obesity and established cardiovascular disease but no diabetes showed roughly a 20% relative reduction in major adverse cardiovascular events.
- Kidney outcome benefit
The FLOW trial in diabetic kidney disease was stopped early for efficacy on a composite kidney endpoint.
- Symptom relief in HFpEF
STEP-HFpEF showed clinically meaningful improvement in heart-failure symptom scores and 6-minute walk distance in obesity-related HFpEF.
Risks & cons — Teduglutide
- Colorectal cancer surveillance required
A drug whose entire mechanism is intestinal growth carries a theoretical neoplasia risk. Colonoscopy is required before starting and periodically thereafter, with polyp removal.
- Bowel obstruction
Mucosal growth can narrow an already compromised lumen; stoma stenosis and obstruction are recognised complications.
- Biliary and pancreatic disease
Cholecystitis, cholangitis and pancreatitis are labelled risks requiring periodic laboratory assessment.
- Fluid overload
Improved absorption can cause fluid overload if parenteral support is not reduced in step — congestive heart failure has been reported.
- Benefit reverses on stopping
The mucosal changes regress after discontinuation; it is indefinite therapy.
Risks & cons — Semaglutide
- Gastrointestinal intolerance
Nausea, vomiting, diarrhea and constipation affect a large minority of users — the single most common reason for stopping. Slow titration mitigates but does not eliminate it.
- Thyroid C-cell tumor boxed warning
Rodents developed medullary thyroid tumors. Human relevance is unproven, but the drug is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.
- Pancreatitis and gallbladder disease
Acute pancreatitis is uncommon but reported. Rapid weight loss raises the rate of cholelithiasis and cholecystitis.
- Loss of lean mass
A meaningful share of total weight lost is fat-free mass. Resistance training and adequate protein intake are standard mitigation, not optional extras.
- Delayed gastric emptying and anesthesia risk
Retained gastric contents have prompted anesthesia societies to issue pre-procedural fasting and withholding guidance because of aspiration risk.
A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.